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A commentary on
Liver FoxP3 and PD1/PDL1 expression is
down-regulated in chronic HBV hepati-
tis on maintained remission related to the
degree of inflammation
by Germanidis G, Argentou N, Hytiroglou
P, Vassiliadis T, Patsiaoura K, Germenis AE,
et al. Front Immunol (2013) 4:207. doi:10.
3389/ fimmu.2013.00207
Recent years have witnessed the devel-
opment of highly effective immunomod-
ulatory therapies, especially for treating
cancers and autoimmune diseases. The
most promising targets include immuno-
suppressive Tregs, characterized by FoxP3
expression, and the inhibitory pathways
involving CTLA-4 and PD-1/PD-L1 mol-
ecules. A recent paper by Germanidis et al.
provides interesting insights into the rel-
evance of these immunosuppressive path-
ways for treating chronic hepatitis B virus
(HBV) hepatitis (CHB) (1).
CHB is characterized by chronic liver
damage, inflammation, and fibrosis, even-
tually leading to cirrhosis and hepatic
carcinoma. The HBV life cycle is not
cytolytic to infected hepatocytes, and the
liver damage is caused by a prolonged
immune response induced by the expres-
sion of HBsAg on infected hepatocytes. The
immune response involves HBsAg-specific
CD8+ CTLs and to a lesser extent CD4+
T effector cells (Teff) (2). CHB is man-
aged with either interferon-based therapies
that act by enhancing anti-viral immune
responses or nucleos(t)ide analogs (NAs),
such as entecavir, which inhibit HBV repli-
cation (3). Successful anti-viral therapy
is characterized by (i) restored anti-viral
immune response, (ii) HBsAg seroconver-
sion, (iii) a decrease in covalently closed cir-
cular DNA (cccDNA), and (iv) a decrease
in circulating HBV DNA (3–5). However,
most patients initially experience “remis-
sion,” followed by HBV reactivation after
treatment withdrawal (3). cccDNA is the
HBV transcription template, it is highly sta-
ble and persists even following resolution
of CHB or acute HBV infection. It enables
HBV reactivation and it is a key hurdle for
achieving complete remission (3).
Elevated levels of intra-hepatic and cir-
culating FoxP3+ Tregs have been described
in CHB and chronic hepatitis C (CHC) (6–
8). In this study, Germanidis et al. reported
down-regulated liver mRNA expression of
FoxP3 and suppressive cytokines, IL-10,
and TGF-β, in patients maintained on-
treatment following 5 years of remission
compared to patients with active disease
and no prior treatment (1). CD8 was
also decreased in patients on-treatment
and in remission. This data suggest a
decrease in both intra-hepatic FoxP3+
Tregs and CTLs following CHB resolu-
tion. Interestingly, IL-2 and IFN-γ expres-
sions were not restored during remission;
this could indicate long-term CTL impair-
ment or else it could be due to a reduc-
tion in intra-hepatic CTLs preventing any
immune response from being restored to
pre-infection intensity.
The role of Tregs in CHB and other
chronic viral infections is not fully clear
and further analyses are required (9, 10).
In vitro Treg depletion can restore the func-
tional activity of virus-specific CTLs (11,
12). In addition, Tregs are expanded in
severe CHB, but correlate with serum viral
load rather than impaired HBV-specific
immune responses (6, 7). In this study,
Germanidis et al. proposed that FoxP3+
Tregs might be expanded non-specifically
in response to chronic liver inflamma-
tion rather than as HBV-specific Tregs
(1). In a previous study, the same group
reported that liver FoxP3 expression is
closely linked to liver inflammation regard-
less of the underlying cause; viral, toxic,
or autoimmunity (13). The current find-
ings confirm FoxP3 is strongly correlated
with inflammation in CHB, in addition
to PD-1, PD-L1, and CD8. FoxP3 expres-
sion also correlated closely with serum
viral load, ALT, and AST (markers of liver
injury). Apoptosis-induced inflammation
is observable in CHB and other liver dis-
eases due to sustained liver injury (14), and
Tregs could prevent catastrophic pathology
due to apoptosis-induced inflammation.
During inflammatory expansion, HBV-
specific Tregs might also be generated in
response to HBsAg on infected hepato-
cytes explaining differing reports regarding
HBV-specific and non-specific Tregs from
CHB patients.
FoxP3 is essential for Treg development
and it is used as the hallmark marker
to identify Tregs in most studies. How-
ever, FoxP3 can be upregulated on non-
suppressive Teff during inflammation and
activation. More specific Treg markers have
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FIGURE 1 | Immunosuppressive mechanisms in CHB active disease and
their resolution upon remission. In active CHB disease, FAS-L and PD-L1
expression are increased on hepatocytes, while TRAIL is down-regulated. (i)
HBsAg-specific CTLs secrete effector cytokines (IL-2 and IFN-γ) inducing
apoptosis in infected hepatocytes expressing HBsAg. (ii) Excessive apoptosis
and pro-inflammatory cytokine secretion induces chronic inflammation, and
the release of inflammatory factors. HBsAg is released from lysed
hepatocytes. (iii) Tregs are expanded in response to inflammatory factors; this
may include both FoxP3+/− Treg subsets. Tregs exert non-specific CTL
suppression. (iv) Circulating Tregs and other immune cells, including NK cells
and MDSCs, migrate toward the site of inflammation contributing to impaired
HBV-specific immune responses. (v) CTLs exhibit an “exhausted” anergic
phenotype characterized by upregulated PD-1 expression. Exhausted CTLs
are unable to exert any immune activity including secretion of effector
cytokines. (vi) HBsAg-presenting APCs induce generation of HBV-specific
Tregs that selectively suppress HBV-specific CTLs. (vii) Circulating
HBV-specific Tregs and HBsAg–APCs are able to induce systemic tolerance to
HBsAg, thus further delaying HBV clearance. Upon remission, FAS-L and
PD-L1 expression are down-regulated, while TRAIL is upregulated.
CD4+FoxP3– T cells may be expanded or persist following resolution of
inflammation, while CTLs do not regain similar functional capacity to
pre-infection.
been identified, as recently reviewed (15).
Therefore, more robust phenotypic and
functional identification of intra-hepatic
suppressive Treg subsets is critical, and
future studies should utilize robust mark-
ers, in vitro suppression assays or TSDR
methylation to confirm the suppressive
Treg status.
This study also reported a positive cor-
relation of PD-1, PD-L1, and the apoptotic
mediators FAS and FAS-L with inflam-
mation intensity (1). The PD-1/PD-L1
pathway is prominent in immune tol-
erance by promoting Treg development
and T cell dysfunction (16). PD-1 and
PD-L1 are upregulated, respectively, on
“exhausted” CTLs in various pathologi-
cal settings and on virally infected hepa-
tocytes (17, 18). PD-1 upregulation has
been characterized during chronic liver
inflammation and, similar to the pro-
posed mechanism for Treg expansion,
upregulation of the PD-1/PD-L1 pathway
might represent a protective mechanism
against chronic inflammation in CHB (17).
Tumor-necrosis factor-related apoptosis-
inducing ligand (TRAIL) was upregulated
during remission and negatively correlated
with inflammation. This might be repre-
sentative of enhanced hepatocyte destruc-
tion during inflammation. Further investi-
gation into TRAIL expression in CHB and
chronic viral inflammation is needed. The
immunosuppressive mechanisms in CHB
active disease and their resolution upon
remission are summarized in Figure 1.
It is important to take into account the
significant heterogeneity of Treg subpop-
ulations. Both FoxP3+ Tregs and FoxP3−
Tregs, such as Tr1 and Th3, exist. Tissue-
specific hepatic Tregs have also been
described (19). Germanidis et al. note that
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in patients in remission, there is no cor-
responding decrease in CD4 with FoxP3
as might be expected with CD4+FoxP3+
Treg reduction. Peripheral Tregs (pTregs),
as opposed to thymic Tregs (tTregs), are
known to be expanded during chronic
inflammation (20). Tregs expanded due
to chronic inflammation could be FoxP3–
pTregs in addition to FoxP3+ pTregs.
Moreover,FoxP3 might also be reduced due
to resolved inflammation.
The unique immune function of the
liver should also be considered when
investigating CHB immunobiology. Vari-
ous subsets of immune cells continuously
traffic into and out of the liver interact-
ing with APCs, including Kupffer cells and
LSECs. This complex network of APCs
and immune-modulating cells maintain
a tolerogenic environment and are able
to induce systemic tolerance in response
to intra-hepatic antigen presentation (21).
Breaking liver-induced systemic HBV tol-
erance might be key to restoring effective
anti-HBV immune responses.
The study by Germanidis et al.
raises some interesting questions regard-
ing immune regulation in CHB. What is
the nature of TRAIL and the FAS/FAS-
L pathway in HBV clearance? What is
the role of other immune regulatory cells
in CHB immune tolerance? Most impor-
tantly, are Tregs and immune-modulating
pathways promoted as a result of chronic
inflammation or the cause for delayed HBV
clearance?
With regards to Tregs as a therapeutic
target, further investigations are required.
Tregs only comprise 1% intra-hepatic
immune cells; expanded B regulatory cells,
NK cells, and myeloid-derived suppressor
cells have all been characterized in CHB
and CHC (8). Immunomodulation could
provide a novel therapeutic approach for
CHB and chronic viral infections. Inter-
estingly, antibody blockade of the PD-
1/PD-L1 pathway restored the activity of
intra-hepatic CTLs in vitro (18, 22). How-
ever, significant challenges remain in bal-
ancing immune activation to clear HBV
infection without inducing further liver
injury (23, 24).
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